Official Title: “A Double-blind, Randomised, Multicenter, Comparative Study of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder”

The primary objective of this study was to compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) after 24 weeks of treatment.

The study hypothesis was that there were clinically important differences between the two drugs in terms of efficacy and adverse event profiles.

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Study Primary Completion Date: September 2006

Depression is a common mental disorder that presents with depressed mood, loss of interest or pleasure, disturbed sleep or appetite, low energy, feelings of guilt or low self-worth, and poor concentration. The lifetime prevalence of Major Depressive Disorder (MDD) in community samples is 10-25% for women and 5-12% for men. Depression may become chronic or recurrent and lead to substantial impairments in an individual's ability to take care of his or her everyday responsibilities. At its worst, depression may lead to suicide. Depression is recurrent in 75-80% of patients and becomes chronic in 15-20% of depressed patients.

The selective serotonin reuptake inhibitors (SSRIs) have become the leading class of antidepressants throughout the world. The efficacy and safety of SSRIs in the treatment of depression has been demonstrated in several clinical trials. With respect to safety, the studies show an advantage for the SSRIs over the older antidepressants. If the prescribing physicians are to make a well-founded judgement in their choice of drug factors like efficacy, safety, quality of life, and health economics must be taken into consideration.

The primary aim of this study is to compare the efficacy of escitalopram with that of the serotonin norepinephrine reuptake inhibitors (SNRIs) duloxetine in the treatment of MDD.

Intervention(s) in this Clinical Trial

• Drug: Escitalopram
  • 20mg once daily; orally
• Drug: Duloxetine
  • 60mg once daily; orally

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Escitalopram
• Active Comparator: Duloxetine

Primary Measures

• To compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) as assessed by change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the end of 24 weeks
  • Time Frame: 24 weeks
    Safety Issue?: No

Secondary Measures

• To compare the efficacy of escitalopram with that of duloxetine per visit over the 24-week study period in outpatients with MDD.
  • Time Frame: Up to 24 weeks
    Safety Issue?: No
• To compare the tolerability and safety of escitalopram with that of duloxetine over the 24-week study period in outpatients with MDD.
  • Time Frame: Up to 24 weeks
    Safety Issue?: Yes
• To evaluate the discontinuation emergent signs and symptoms during and after taper-down treatment with escitalopram or duloxetine after 24 weeks of treatment assessed by the Discontinuation Emergent Signs and Symptoms Scale (DESS).
  • Time Frame: Up to 24 weeks
    Safety Issue?: Yes

Inclusion Criteria:

• The patient suffers from a primary diagnosis of MDD according to DSM-IV-TR criteria (classification code 296.xx; current episode assessed using the MINI)
• The patient has a MADRS total score >=26 and a CGI-S score >=4 at the Baseline Visit

Exclusion Criteria:

• Any current psychiatric disorder other than MDD as defined in the DSM-IV TR
• Female patients of childbearing potential who are not using effective contraception
• Use of any psychoactive medication 2 weeks prior to screening and during the study
• Other protocol-defined inclusion and exclusion criteria may apply.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: H. Lundbeck A/S

Overall Clinical Trial Officials and Contacts

Email contact via H. Lundbeck A/S Study Director LundbeckClinicalTrials@lundbeck.com  

Information obtained from ClinicalTrials.gov on September 01, 2010

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01148472

Study ID Number: 10990

ClinicalTrials.gov Identifier: NCT01148472

Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products